2025-04-23 - Analysis Report
## Colgate-Palmolive Co (CL) Stock Review

**0) Key Figures & Initial Analysis:**

Colgate-Palmolive Co (CL) is a leading consumer goods company specializing in oral care, personal care, and home care products.  The company's cumulative return significantly underperformed the S&P 500 (VOO) over the analyzed period.

**1) Performance Comparison with S&P 500 (VOO):**

* **CL Cumulative Return:** 42.36%
* **VOO Cumulative Return:** 76.31%
* **Return Difference:** -33.9%
* **Relative Divergence:** 44.0% (This indicates that CL's underperformance relative to VOO is in the 44th percentile of its historical range of under/out-performance.)

The provided Alpha and Beta analysis shows mixed results across different time periods, with positive alpha in some years indicating outperformance and negative alpha in others showing underperformance against the market. Beta consistently remains above 0.1 indicating higher volatility than the market.  Capitalization (Cap) fluctuates, suggesting changes in market valuation.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 16.0% | 4.2% | -16.0% | 0.1 | 51.2 |
| 2016-2018  | -9.0% | 65.3% | -30.0% | 0.1 | 41.4 |
| 2017-2019  | 10.0% | 65.3% | -24.0% | -0.3 | 49.1 |
| 2018-2020  | 22.0% | 65.3% | -8.0% | 0.3 | 62.4 |
| 2019-2021  | 34.0% | 58.5% | -26.0% | 0.8 | 63.7 |
| 2020-2022  | 11.0% | 68.9% | 2.0% | 0.7 | 60.3 |
| 2021-2023  | 8.0% | 68.9% | -13.0% | 0.6 | 62.5 |
| 2022-2024  | 16.0% | 68.9% | -5.0% | 0.5 | 72.9 |
| 2023-2025  | 20.0% | 62.4% | 5.0% | 0.3 | 77.7 |


**2) Recent Price Movement:**

* **Closing Price:** $95.81
* **5-Day Moving Average:** $94.54
* **20-Day Moving Average:** $92.51
* **60-Day Moving Average:** $90.34

The price is above all three moving averages, suggesting a short-term uptrend.  The recent increase of $1.17 (from $94.70) shows a slight positive momentum.


**3) Technical Indicators & Expected Return:**

* **Market Risk Indicator (MRI):** 0.435 (Low to Medium Risk)
* **RSI:** 55.43 (Slightly above neutral; neither overbought nor oversold)
* **PPO:** 0.399 (Positive, suggesting bullish momentum)
* **20-Day Relative Divergence Change:** +7.1 (Short-term upward trend)
* **Expected Return:** -47.3% (This suggests a significant underperformance relative to the S&P 500 over the long term (2+ years), if current trends continue.) The negative expected return warrants a closer examination of the factors contributing to this prediction.

**4) Recent Earnings Analysis:**

| Date       | EPS    | Revenue      |
|------------|--------|--------------|
| 2024-10-25 | $0.90  | $5.03B       |
| 2024-07-26 | $0.89  | $5.06B       |
| 2024-04-26 | $0.83  | $5.07B       |
| 2023-10-27 | $0.86  | $4.92B       |
| 2024-10-25 | $0.86  | $4.92B       |


Earnings show relatively stable revenue around $5B, with slight fluctuations. EPS also shows minor variations, requiring further investigation into the reasons for these changes.  Note that there's a duplicate entry for 2024-10-25; data inconsistencies should be addressed.

**5) Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $4.95B | 60.30% |
| 2024-09-30 | $5.03B | 61.08% |
| 2024-06-30 | $5.06B | 60.62% |
| 2024-03-31 | $5.07B | 60.00% |
| 2023-12-31 | $4.95B | 59.60% |

Revenue remains relatively consistent. Profit margins are high and stable, suggesting strong profitability.

**Capital and Profitability:**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2024-12-31 | $0.21B | 348.58% |
| 2024-09-30 | $0.43B | 169.43% |
| 2024-06-30 | $0.12B | 594.31% |
| 2024-03-31 | $0.23B | 296.96% |
| 2023-12-31 | $0.61B | 117.90% |

Equity and ROE show significant volatility.  The extremely high ROE values in some quarters require further investigation to determine if they reflect unusual accounting practices or other factors.


**6) Overall Conclusion:**

CL's performance has lagged behind the S&P 500 significantly. While recent price action suggests a short-term uptrend, the substantial negative expected return and the volatility in financial metrics raise concerns.  The high and fluctuating ROE values require a deeper analysis to understand the underlying drivers.  Further investigation is needed into the reasons for the persistent underperformance against the market, the inconsistencies in the earnings data, and the highly volatile ROE figures before forming a definitive investment opinion.  A thorough examination of the company's competitive landscape, strategic initiatives, and potential risks is crucial for a comprehensive assessment.
